- Reviva Pharmaceuticals Holdings Inc (NASDAQ:RVPH) is trading higher with around 60k in session volume.
- Maxim initiated coverage of Reviva with a Buy rating and $10 price target, equivalent to an upside of around 140%.
- The company is developing its lead asset, RP5063 (brilaroxazine), to treat schizophrenia and respiratory indications.
- Analyst Jason McCarthy tells in a research note that RP5063 features a multimodal mechanism of action, which is “more completely” addressing the mix of positive, negative, and cognitive symptoms associated with schizophrenia.
- In April, RP5063 showed positive action in the schizophrenia trial that met its primary endpoint of disease severity versus placebo.
- Price Action: RVPH shares are up 9.92% at $4.21 during the market session on the last check Monday.
Johnson & Johnson’s Drug Acquired Via Momenta Deal Shows Encouraging Data In Fetal Disorder
Janssen, a unit of Johnson & Johnson (NYSE:JNJ), announced topline results from the proof-of-concept Phase 2 open-label UNITY trial for…
